Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.

Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM.

Neuro Oncol. 2016 Mar;18(3):368-78. doi: 10.1093/neuonc/nov153. Epub 2015 Sep 1.

2.

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells.

Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM.

J Immunother Cancer. 2014 Apr 15;2:8. doi: 10.1186/2051-1426-2-8. eCollection 2014.

3.

Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.

Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM.

J Immunother Cancer. 2014 May 13;2:10. doi: 10.1186/2051-1426-2-10. eCollection 2014.

4.

An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity.

Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN, Komisopoulou E, Henkin AH, Soto H, Chamberlain BT, Vergnes L, Jung ME, Torres JZ, Liau LM, Christofk HR, Prins RM, Mischel PS, Reue K, Graeber TG, Bensinger SJ.

Cancer Res. 2013 May 1;73(9):2850-62. doi: 10.1158/0008-5472.CAN-13-0382-T. Epub 2013 Feb 25.

5.

Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.

Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM.

J Immunother. 2013 Feb;36(2):152-7. doi: 10.1097/CJI.0b013e3182811ae4.

6.

Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients.

Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, Prins RM.

PLoS One. 2012;7(4):e32614. doi: 10.1371/journal.pone.0032614. Epub 2012 Apr 2. Erratum in: PLoS One. 2012;7(4): doi/10.1371/annotation/641c3e73-ee2c-4873-8896-1b3a2edc557b. PLoS One. 2012;7(4): doi/10.1371/annotation/921cda8a-d169-49b8-9dfc-5ee32271b729.

7.

Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.

Lisiero DN, Soto H, Liau LM, Prins RM.

J Immunol. 2011 May 1;186(9):5068-77. doi: 10.4049/jimmunol.1003317. Epub 2011 Mar 23.

Supplemental Content

Loading ...
Support Center